J. Gregory Cairncross

58.5k total citations · 6 hit papers
169 papers, 36.1k citations indexed

About

J. Gregory Cairncross is a scholar working on Genetics, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. Gregory Cairncross has authored 169 papers receiving a total of 36.1k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Genetics, 59 papers in Molecular Biology and 56 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. Gregory Cairncross's work include Glioma Diagnosis and Treatment (131 papers), Brain Metastases and Treatment (51 papers) and Radiomics and Machine Learning in Medical Imaging (20 papers). J. Gregory Cairncross is often cited by papers focused on Glioma Diagnosis and Treatment (131 papers), Brain Metastases and Treatment (51 papers) and Radiomics and Machine Learning in Medical Imaging (20 papers). J. Gregory Cairncross collaborates with scholars based in Canada, United States and Germany. J. Gregory Cairncross's co-authors include Roger Stupp, Warren Mason, Michael Weller, R.O. Mirimanoff, Thierry Gorlia, Robert C. Janzer, Martin J. van den Bent, David R. Macdonald, Alba A. Brandes and Denis Lacombe and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

J. Gregory Cairncross

168 papers receiving 35.4k citations

Hit Papers

Radiotherapy plus Concomitant and Adjuvant Temozol... 1990 2026 2002 2014 2005 2005 1990 1998 2003 5.0k 10.0k 15.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
    2005 16.0k citations Roger Stupp, Warren Mason et al. New England Journal of Medicine profile →
  2. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
    2005 5.2k citations Monika E. Hegi, Annie‐Claire Diserens et al. New England Journal of Medicine profile →
  3. Response criteria for phase II studies of supratentorial malignant glioma.
    1990 2.0k citations David R. Macdonald, J. Gregory Cairncross et al. Journal of Clinical Oncology profile →
  4. Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic Oligodendrogliomas
    1998 1.2k citations J. Gregory Cairncross, David R. Macdonald et al. profile →
  5. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.
    2003 719 citations Catherine L. Nutt, J. Gregory Cairncross et al. PubMed profile →
  6. Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma
    2008 566 citations Thierry Gorlia, Marie‐France Hamou et al. Journal of Clinical Oncology profile →

Peers

J. Gregory Cairncross
Alba A. Brandes Italy
Thierry Gorlia Belgium
Hiroko Ohgaki France
Warren Mason Canada
Henry S. Friedman United States
Otmar D. Wiestler Germany
Patrick Y. Wen United States
R.O. Mirimanoff Switzerland
Guido Reifenberger Germany
Jill S. Barnholtz‐Sloan United States
Alba A. Brandes Italy
J. Gregory Cairncross
Citations per year, relative to J. Gregory Cairncross J. Gregory Cairncross (= 1×) peers Alba A. Brandes

Countries citing papers authored by J. Gregory Cairncross

Since Specialization
Citations

This map shows the geographic impact of J. Gregory Cairncross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Gregory Cairncross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Gregory Cairncross more than expected).

Fields of papers citing papers by J. Gregory Cairncross

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Gregory Cairncross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Gregory Cairncross. The network helps show where J. Gregory Cairncross may publish in the future.

Co-authorship network of co-authors of J. Gregory Cairncross

This figure shows the co-authorship network connecting the top 25 collaborators of J. Gregory Cairncross. A scholar is included among the top collaborators of J. Gregory Cairncross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Gregory Cairncross. J. Gregory Cairncross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cairncross, J. Gregory, Jonathan D. Hall, & Craig Palsson. (2025). VancUber: The long‐run effect of ride‐hailing on public transportation, congestion, and traffic fatalities. Canadian Journal of Economics/Revue canadienne d économique. 58(3). 892–939.
2.
Huang, Jiayi, Jian Campian, T.A. DeWees, et al.. (2024). A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma. International Journal of Radiation Oncology*Biology*Physics. 120(3). 738–749. 11 indexed citations
3.
Lassman, Andrew B., Khê Hoang‐Xuan, Mei‐Yin C. Polley, et al.. (2022). Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology. 40(23). 2539–2545. 43 indexed citations
4.
Song, Andrew, Keyue Ding, Iyad Alnahhas, et al.. (2021). Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG08.02) randomized clinical trial. Neuro-Oncology Advances. 3(1). vdab153–vdab153. 12 indexed citations
5.
Brandes, Alba A., J. Gregory Cairncross, Keyue Ding, et al.. (2020). Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. Journal of Neuro-Oncology. 149(1). 65–71. 17 indexed citations
6.
Viswanath, Pavithra, Marina Radoul, José Luis Izquierdo-García, et al.. (2018). 2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas. Cancer Research. 78(9). 2290–2304. 40 indexed citations
7.
Viswanath, Pavithra, Marina Radoul, José Luis Izquierdo-García, et al.. (2018). Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner. SHILAP Revista de lepidopterología. 6(1). 3–3. 35 indexed citations
8.
Lun, Xueqing, J. Connor Wells, Natalie Grinshtein, et al.. (2016). Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. Clinical Cancer Research. 22(15). 3860–3875. 169 indexed citations
9.
Louis, David N., Ken Aldape, Daniel J. Brat, et al.. (2016). cIMPACT‐NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathology. 27(6). 851–852. 52 indexed citations
10.
Izquierdo-García, José Luis, Pavithra Viswanath, Pia Eriksson, et al.. (2015). IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. Cancer Research. 75(15). 2999–3009. 98 indexed citations
11.
Nguyen, Stephanie A., Owen D.M. Stechishin, H. Artee Luchman, et al.. (2014). Novel MSH6 Mutations in Treatment-Naïve Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of MGMT Promoter Methylation. Clinical Cancer Research. 20(18). 4894–4903. 50 indexed citations
12.
Cairncross, J. Gregory, Meihua Wang, Robert B. Jenkins, et al.. (2014). Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH. Journal of Clinical Oncology. 32(8). 783–790. 285 indexed citations
13.
Luchman, H. Artee, Owen D.M. Stechishin, Stephanie A. Nguyen, et al.. (2014). Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival. Clinical Cancer Research. 20(22). 5756–5767. 44 indexed citations
14.
Stechishin, Owen D.M., H. Artee Luchman, Yibing Ruan, et al.. (2012). On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells. Neuro-Oncology. 15(2). 198–207. 86 indexed citations
15.
Hegi, Monika E., Annie‐Claire Diserens, Thierry Gorlia, et al.. (2005). MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. New England Journal of Medicine. 352(10). 997–1003. 5232 indexed citations breakdown →
16.
Stupp, Roger, Warren Mason, Martin J. van den Bent, et al.. (2005). Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine. 352(10). 987–996. 15995 indexed citations breakdown →
17.
Nutt, Catherine L., Mark Noble, Ann F. Chambers, & J. Gregory Cairncross. (2000). Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy.. PubMed. 60(17). 4812–8. 81 indexed citations
18.
Rock, Jack, Mark L. Rosenblum, Edward G. Shaw, & J. Gregory Cairncross. (1999). The practical management of low-grade primary brain tumors. Lippincott Williams & Wilkins eBooks. 23 indexed citations
19.
Peterson, Kendra & J. Gregory Cairncross. (1996). Oligodendroglioma. Cancer Investigation. 14(3). 243–251. 9 indexed citations
20.
Mattes, M. Jules, J. Gregory Cairncross, Lloyd J. Old, & Kenneth O. Lloyd. (1983). Monoclonal Antibodies to Three Widely Distributed Human Cell Surface Antigens. Hybridoma. 2(3). 253–264. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alba A. Brandes Breakdown of academic impact, for papers by Thierry Gorlia Breakdown of academic impact, for papers by Hiroko Ohgaki Breakdown of academic impact, for papers by Warren Mason Breakdown of academic impact, for papers by Henry S. Friedman Breakdown of academic impact, for papers by Otmar D. Wiestler Breakdown of academic impact, for papers by Patrick Y. Wen Breakdown of academic impact, for papers by R.O. Mirimanoff Breakdown of academic impact, for papers by Guido Reifenberger Breakdown of academic impact, for papers by Jill S. Barnholtz‐Sloan
Rankless by CCL
2026